UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

Journal: Nature Genetics

Published: 2018-05-07

DOI: 10.1038/s41588-018-0114-z

Affiliations: 18

Authors: 27

Go to article
Institutions FC
Sanger Institute Haematological Cancer Genetics Group, United Kingdom (UK) 0.31
Wellcome Trust - MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom (UK) 0.15
Sanger Institute Proteomic Mass Spectrometry Group, United Kingdom (UK) 0.11
Sanger Institute Experimental Cancer Genetics, United Kingdom (UK) 0.07
Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), Spain 0.04
Institute of Industrial Science (IIS), UTokyo, Japan 0.04
Wellcome Trust Genome Campus, United Kingdom (UK) 0.04
Sanger Institute Vertebrate Resequencing Group, United Kingdom (UK) 0.04
Sanger Institute Mouse Genomes Project, United Kingdom (UK) 0.04
Sanger Institute Genomics of Gene Regulation Group, United Kingdom (UK) 0.04
Cambridge Institute for Medical Research (CIMR), University of Cambridge, United Kingdom (UK) 0.02
Department of Haematology, University of Cambridge, United Kingdom (UK) 0.02
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK) 0.02
Department of Internal Medicine III, Ulm University, Germany 0.02
Charité Medical Department - Division of Hematology, Oncology and Tumor Immunology, Germany 0.02
Division of Pediatric Neurooncology, DKFZ, Germany 0.02
St. Jude Children's Research Hospital (St. Jude), United States of America (USA) 0.02

Return